drugset / Trial / NCT06959732
Zanubrutinib Combined With G-CVP in Previously Untreated FL
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to learn the efficacy and safety of zanubrutinib in combination with G-CVP in previously untreated follicular lymphoma patients The main questions it aims to answer are: (1) Efficacy and safety of patients receiving zanubrutinib, obinutuzumab combined with cyclophosphamide, vincristine, and prednisone (CVP) regimen. (2) The difference in efficacy of patients with different minimal residual disease (MRD) status after treatment. Participants will receive zanubrutinib combined with G-CVP, maintenance therapy will be determined by the MRD status after treatment.
Timeline
- Start
- 2025-01-01
- Primary completion
- 2027-06-30
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 750 mg/m2 | — |
| Subject | Obinutuzumab | Monoclonal antibody | 1000 mg | — |
| Subject | Prednisone | Other / unclassified | 40 mg/m2 | Oral |
| Subject | Vincristine | Small molecule | 1.4 mg/m2 | — |
| Subject | Zanubrutinib | Small molecule | 160 mg | — |